[
  {
    "question": "Patient with myotonia what's associated with it",
    "option_a": "(Diabetes) is correct because myotonic dystrophy is strongly linked with insulin resistance and subsequent type 2 diabetes. Option B (Hypertension), Option C (Malignancy), and Option D (Osteolytic bone lesions) are not typical systemic manifestations or associations of myotonic dystrophy.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonia refers to the prolonged relaxation of muscles following contraction. In the context of systemic diseases such as myotonic dystrophy (especially type 1), myotonia is accompanied by multisystem involvement, including endocrine disturbances. One of the well\u2010recognized associations is insulin resistance leading to type 2 diabetes mellitus. Myotonic dystrophy type 1 is caused by an autosomal dominant CTG trinucleotide repeat expansion in the DMPK gene. The resulting RNA toxicity leads to aberrant alternative splicing of multiple target proteins, including the insulin receptor. This abnormal splicing may impair insulin signalling, thereby predisposing patients to insulin resistance and eventually type 2 diabetes mellitus. Patients with myotonic dystrophy typically present with muscle stiffness and myotonia, along with features such as cataracts, cardiac conduction defects, and endocrine abnormalities. The presence of diabetes in a patient with myotonia is a red flag for an underlying systemic myopathic process rather than an isolated muscle channelopathy. Key differential diagnoses include other causes of myotonia such as myotonia congenita and paramyotonia congenita. Detailed clinical history, family history, electromyography (EMG), and genetic testing to detect CTG repeat expansions are essential for diagnosis. Meanwhile, serum glucose and insulin levels help detect the metabolic complications. Management is multidisciplinary. First\u2010line treatment is supportive care and symptomatic management of myotonia (using drugs like mexiletine). Endocrine complications such as diabetes should be managed according to standard diabetology guidelines. Cardiac monitoring is essential. In pregnancy and lactation, glycemic control is critical, and medications should be chosen carefully with obstetric consultation to avoid teratogenic effects. Option A (Diabetes) is correct because myotonic dystrophy is strongly linked with insulin resistance and subsequent type 2 diabetes. Option B (Hypertension), Option C (Malignancy), and Option D (Osteolytic bone lesions) are not typical systemic manifestations or associations of myotonic dystrophy. 1. Myotonic dystrophy not only affects muscles but also has significant systemic and endocrine involvement. 2. Always consider a screening for diabetes in patients with myotonia. 3. Genetic testing is crucial for diagnosing myotonic dystrophy and guiding family counseling. Recent research continues to emphasize the multisystem nature of myotonic dystrophy, with studies focusing on the molecular mechanisms underpinning the abnormal splicing events. Updated clinical guidelines advocate for regular screening for cardiac and endocrine complications, including early detection of insulin resistance.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "35 years old female has hx of back pain, also she has progressive weakness, with normal brain & spine MRI, he mentioned she came from Africa:",
    "option_a": "Vacuolar myelopathy (painless, no back pain), if no back pain -> it is the answer",
    "option_b": "Lymphoma",
    "option_c": "HTLV-1",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The scenario describes a patient with progressive weakness and a history of back pain, along with a normal brain and spine MRI. In a patient hailing from an endemic area (Africa), an infectious or immune\u2010mediated cause of myelopathy should be considered. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is due to a chronic immune-mediated inflammatory response triggered by the human T-lymphotropic virus type 1. The inflammatory process affects the spinal cord, particularly the thoracic segment, leading to demyelination and axonal degeneration. Clinically, HTLV-1 associated myelopathy presents with slowly progressive spastic paraparesis, gait disturbances, and bladder dysfunction. Despite significant clinical symptoms, early stages might show normal imaging findings. The patient\u2019s background from Africa adds epidemiologic support to this diagnosis. The differential diagnoses include HIV-associated vacuolar myelopathy (which typically is painless and may occur without back pain), primary CNS lymphoma (which would usually be visible on imaging with mass effect), and other causes of chronic myelopathy like vitamin deficiencies. Confirmation of HTLV-1 infection is established via serologic testing and polymerase chain reaction (PCR). Management is largely supportive. First-line treatment may involve corticosteroids to dampen the immune-mediated inflammation, and physical therapy is crucial for maintaining mobility. There is ongoing research into immunomodulatory therapies. In pregnant or lactating patients, corticosteroid use requires careful monitoring, and the potential risks and benefits must be weighed with obstetric consultation. Option A (Vacuolar myelopathy) is less likely because it is generally seen in HIV patients and is characteristically painless, whereas this patient has back pain. Option B (Lymphoma) would typically produce MRI abnormalities due to mass effect. Option C (HTLV-1) is the most fitting diagnosis given the epidemiologic context and clinical presentation. 1. HTLV-1 associated myelopathy should be suspected in patients from endemic regions with unexplained spastic paraparesis. 2. Normal imaging does not exclude inflammatory myelopathies in early disease stages. 3. Always confirm HTLV-1 infection with specific serologic or PCR tests. Current guidelines emphasize the importance of recognizing HTLV-1 as a cause of chronic myelopathy especially in endemic areas, with emerging studies evaluating the efficacy of early immunomodulatory interventions to improve long-term outcomes.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of Crohn's disease underwent resection with fat in the stool presented with ataxia and decreased reflexes, myelopathy. what is the diagnosis?",
    "option_a": "(Vitamin E deficiency) is correct because it directly links fat malabsorption with neurologic deficits seen in the patient. Option B (Vitamin B12 deficiency) is incorrect since B12 is water",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Patients with Crohn's disease, particularly those who have undergone intestinal resection, are at risk for fat malabsorption. Fat malabsorption can lead to deficiencies in fat-soluble vitamins, including vitamin E, which is essential for neurological function. Vitamin E functions as a potent antioxidant, protecting neural tissues from oxidative damage. In conditions of fat malabsorption, such as post-resective Crohn\u2019s disease with steatorrhea, decreased vitamin E absorption leads to its deficiency. This deficiency can cause a range of neurological manifestations, including spinocerebellar ataxia, peripheral neuropathy, and myelopathy. The patient\u2019s history of Crohn\u2019s disease with resection and evidence of steatorrhea (fat in the stool) aligns with the development of a fat-soluble vitamin deficiency. Neurological findings of ataxia, decreased reflexes, and signs of myelopathy are consistent with vitamin E deficiency. In contrast, vitamin B12 deficiency, though it may cause myelopathy, typically presents with hyperreflexia and megaloblastic anemia. Differential diagnoses include vitamin B12 deficiency, which classically causes subacute combined degeneration of the spinal cord, and other neurodegenerative disorders. The presence of fat malabsorption and steatorrhea favors vitamin E deficiency. Laboratory assays measuring serum vitamin E levels, along with a detailed nutritional history, aid in the diagnosis. First-line management is supplementation with vitamin E, alongside optimization of nutritional absorption in patients with Crohn\u2019s disease. Dietary modifications and possibly the use of medium-chain triglycerides may improve vitamin absorption. In pregnancy and lactation, vitamin E supplementation is generally safe, but the dosage should be carefully monitored to avoid hypervitaminosis, and coordination with obstetric care is essential. Option A (Vitamin E deficiency) is correct because it directly links fat malabsorption with neurologic deficits seen in the patient. Option B (Vitamin B12 deficiency) is incorrect since B12 is water-soluble, and its deficiency typically presents with additional hematological findings and often hyperactive reflexes. 1. Fat malabsorption following intestinal resection puts patients at high risk for fat-soluble vitamin deficiencies. 2. Vitamin E deficiency can lead to a spinocerebellar syndrome with ataxia and peripheral neuropathy. 3. Always consider the nutritional status in patients with a history of Crohn\u2019s disease post-resection. Recent studies have highlighted the frequency of fat-soluble vitamin deficiencies in patients with inflammatory bowel disease, emphasizing the need for routine nutritional assessments. Updated guidelines suggest proactive supplementation and periodic monitoring to prevent neurological complications.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with pic of MG (eve. proximal weakness and bulbar) with flat tongue (atrophy) which of the",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": ", meaning that none of the options that solely support MG is correct) since the presence of tongue atrophy is inconsistent with the diagnosis of MG. Any option that disregards the significance of atrophy in the tongue misses the critical diagnostic feature that suggests an alternative process such as ALS.",
    "correct_answer": "E",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular junction, leading to fluctuating weakness, particularly affecting ocular, bulbar, and proximal muscles. Importantly, MG characteristically does not cause muscle atrophy because the pathology is functional rather than destructive. In MG, antibodies (commonly against the acetylcholine receptor or MuSK) impair synaptic transmission at the neuromuscular junction. The resultant impairment in muscle activation causes fatigable weakness without generating direct muscle fiber damage \u2013 a contrast to degenerative conditions where denervation or direct myopathic damage leads to atrophy. The clinical picture described (proximal and bulbar weakness) is consistent with MG, yet the presence of tongue atrophy is atypical for this disorder. Tongue atrophy is more suggestive of a lower motor neuron pathology such as amyotrophic lateral sclerosis (ALS), which also features bulbar symptoms along with fasciculations and progressive muscle wasting. Differential diagnoses include myasthenia gravis, ALS, and inflammatory myopathies. Key differentiators include the presence of muscle atrophy and fasciculations (seen in ALS), versus fatigable weakness without atrophy (seen in MG). Diagnostic tests such as repetitive nerve stimulation, single-fiber EMG, and antibody assays for acetylcholine receptor and MuSK are crucial for MG, while EMG and clinical criteria support ALS. MG management primarily involves acetylcholinesterase inhibitors (e.g., pyridostigmine) as first-line therapy, followed by immunosuppressive agents (e.g., corticosteroids, azathioprine) as second-line therapy, and thymectomy in selected cases. During pregnancy and lactation, pyridostigmine is generally considered safe. However, immunosuppressants require close coordination with obstetrics due to potential risks. The presence of tongue atrophy should prompt clinicians to reconsider the diagnosis and evaluate for conditions like ALS, which have entirely different management strategies. The correct answer here is 'None' (or option E, meaning that none of the options that solely support MG is correct) since the presence of tongue atrophy is inconsistent with the diagnosis of MG. Any option that disregards the significance of atrophy in the tongue misses the critical diagnostic feature that suggests an alternative process such as ALS. 1. MG typically features fluctuating weakness without muscle atrophy. 2. Tongue atrophy is a red flag for motor neuron disease such as ALS. 3. Differentiation between MG and ALS is essential because the management of an autoimmune disorder versus a neurodegenerative disease is vastly different. Ongoing research and updated clinical guidelines emphasize the importance of thorough neuromuscular evaluation when atypical features, such as muscle atrophy, are present in patients initially suspected of having MG. Biomarkers and advanced electrodiagnostic studies are increasingly used to expedite the correct diagnosis.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Diabetic patient with feature of small fiber neuropathy (pain worse at night, intact reflexes) what is the best treatment.",
    "option_a": "(Pregabalin) is correct because robust evidence supports its efficacy and safety in diabetic neuropathic pain. Option B (Amitriptyline) is effective but generally reserved as a second",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Diabetic small fiber neuropathy involves preferential damage to small-diameter sensory fibers. These fibers are responsible for transmitting pain and temperature sensations. The condition often presents with burning pain, particularly at night, while deep tendon reflexes remain intact because large myelinated fibers are less affected. Chronic hyperglycemia in diabetes leads to metabolic and microvascular injury, causing axonal degeneration and demyelination, especially in small fibers. The resulting abnormal nerve excitability and altered pain processing lead to neuropathic pain. Pregabalin acts by binding to the \u03b12\u03b4 subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters. Patients typically report burning, shooting, or tingling pain that worsens at night. The preservation of reflexes distinguishes small fiber neuropathy from other sensorimotor neuropathies that involve large fibers. This neuropathy is a common complication in diabetes and may occur even with acceptable glycemic control. The diagnosis is primarily clinical but can be supported by quantitative sensory testing, skin biopsy for nerve fiber density, or other specialized tests. Differential diagnoses include post-herpetic neuralgia, idiopathic small fiber neuropathy, and other metabolic or toxic neuropathies. Electrophysiological studies may be normal, as conventional nerve conduction studies assess large fibers. For painful diabetic neuropathy, first-line agents include pregabalin, gabapentin, and duloxetine. Pregabalin is FDA-approved and preferred due to its efficacy and safety profile. In patients who are pregnant or lactating, careful risk-benefit discussion is needed as data on safety is limited; non-pharmacologic therapies should also be considered, and if pharmacotherapy is required, agents with better-established safety data in pregnancy (such as certain antidepressants) might be considered. Option A (Pregabalin) is correct because robust evidence supports its efficacy and safety in diabetic neuropathic pain. Option B (Amitriptyline) is effective but generally reserved as a second-line agent due to anticholinergic and cardiac risks, particularly in older or comorbid patients. 1. Diabetic small fiber neuropathy often presents with burning pain that worsens at night while reflexes remain intact. 2. Pregabalin is favored as a first-line treatment due to its rapid onset and FDA approval for this indication. Recent guidelines emphasize early recognition and multimodal treatment of neuropathic pain in diabetes. Current research continues to compare pregabalin with other agents like duloxetine, and studies are exploring biomarkers for early detection of small fiber neuropathy.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Young patient with distal myopathy (posterior calf) and high CK 7000",
    "option_a": "",
    "option_b": "(Miyoshi myopathy) is correct as it best matches the clinical presentation of distal (posterior calf) weakness and markedly elevated CK. Option A (Nemaline myopathy) and Option C (Nonaka myopathy) are less likely considering the distinct pattern of muscle involvement and CK levels described.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Distal myopathies are a heterogeneous group of muscular disorders that primarily affect the distal muscles. Miyoshi myopathy is a form of distal myopathy that predominantly involves the posterior calf muscles. Miyoshi myopathy is an autosomal recessive disorder caused by mutations in the dysferlin gene. Dysferlin is essential for muscle membrane repair; its deficiency leads to progressive necrosis and replacement of muscle tissue with fat and fibrous tissue. This process results in markedly elevated serum CK levels due to ongoing muscle breakdown. Patients, often young adults, present with early involvement of the posterior calf muscles characterized by difficulty in tasks such as tiptoeing and rising on the toes. The marked elevation of CK (often >7000 U/L) alongside clinical findings supports the diagnosis. The evaluation includes serum CK measurement, electromyography (EMG), and muscle biopsy with immunohistochemistry to assess dysferlin expression. Differential diagnoses include Nonaka myopathy, which typically presents with anterior tibial weakness (foot drop) and lower CK elevations, and other muscular dystrophies such as distal limb-girdle myopathies. Currently, there is no curative treatment for Miyoshi myopathy. Management is supportive, focusing on physical therapy to maintain mobility, orthotic support, and symptomatic care. Genetic counseling is essential. In pregnant or lactating patients, supportive therapies remain the mainstay as pharmacologic treatments are not available. Option B (Miyoshi myopathy) is correct as it best matches the clinical presentation of distal (posterior calf) weakness and markedly elevated CK. Option A (Nemaline myopathy) and Option C (Nonaka myopathy) are less likely considering the distinct pattern of muscle involvement and CK levels described. 1. A very high CK level in a young patient with distal calf weakness should raise suspicion for Miyoshi myopathy. 2. Dysferlin deficiency is a key diagnostic marker, confirmed via immunohistochemistry or genetic testing. Recent studies focus on the underlying molecular mechanisms of dysferlinopathy and potential gene therapy approaches. Advances in molecular diagnostics have improved accuracy in differentiating among various distal myopathies.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with findings suggestive of dermatomyositis (hints: dermal lesions, myopathy....) asked about biopsy finding?",
    "option_a": "rimmed vacuole",
    "option_b": "Perifascicular atrophy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Dermatomyositis is an idiopathic inflammatory myopathy characterized by distinctive skin manifestations and proximal muscle weakness. The hallmark histopathological feature in muscle biopsy is perifascicular atrophy. The disease is mediated by a complement-driven microangiopathy resulting in capillary destruction and subsequent muscle fiber ischemia. This primarily affects the perifascicular areas of the muscle, leading to atrophy. Autoimmune mechanisms involving type I interferon pathways play a central role in the pathogenesis. Patients typically present with skin changes such as heliotrope rash and Gottron papules along with proximal muscle weakness. Perifascicular atrophy on muscle biopsy correlates with the vascular compromise observed in these patients. The diagnosis is based on a combination of clinical findings (skin rash, muscle weakness), laboratory studies (elevated muscle enzymes, autoantibodies), electromyography, and muscle biopsy. Differential diagnoses include polymyositis (which lacks skin involvement) and inclusion body myositis (characterized by rimmed vacuoles). First-line therapy for dermatomyositis is high-dose corticosteroids, typically initiated with prednisone. Second-line agents include methotrexate or azathioprine, especially in cases of steroid resistance or when steroid-sparing is desired. In pregnancy and lactation, corticosteroids remain the mainstay of treatment as they have a relatively good safety profile; immunosuppressants such as azathioprine can also be considered with careful monitoring. Option B (Perifascicular atrophy) is correct as it is the classic biopsy finding in dermatomyositis. Option A (Rimmed vacuoles) is more indicative of inclusion body myositis, which is less common and typically occurs in older adults. 1. The presence of a typical skin rash (heliotrope and Gottron papules) with proximal muscle weakness should raise suspicion for dermatomyositis. 2. Perifascicular atrophy on muscle biopsy is a key diagnostic feature. Recent guidelines have emphasized early aggressive treatment with corticosteroids to prevent long-term disability. Additionally, there is growing evidence on the utility of intravenous immunoglobulin (IVIG) and biologics in refractory cases, although these require careful consideration in pregnant and lactating patients.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case of myotonia induced after repetitive exercise then develop weakness, positive Family History, dx?",
    "option_a": "Paramyotonia congenita",
    "option_b": "Myotonic dystrophy",
    "option_c": "Myotonia congenita",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonia refers to delayed relaxation after muscle contraction, and it can be seen in various hereditary myotonic disorders. Paramyotonia congenita is one of these non-dystrophic myotonias, characterized by paradoxical worsening of myotonia with repetitive activity and exposure to cold. Paramyotonia congenita is usually caused by mutations in the SCN4A gene, which encodes a voltage-gated sodium channel in skeletal muscle. These mutations result in abnormal channel function, leading to prolonged depolarization and repetitive firing of muscle fibers. Unlike typical myotonia congenita (which shows a warm-up phenomenon), paramyotonia demonstrates a paradoxical worsening of stiffness and even transient weakness upon repeated use. Patients often report that muscle stiffness and weakness worsen with repetitive activity and cold exposure. A positive family history supports the autosomal dominant inheritance of the disorder. The clinical presentation is distinct from myotonic dystrophy, which usually presents with multisystem involvement (cardiac conduction defects, cataracts, endocrine issues). Diagnosis is based on clinical history, electromyography showing characteristic myotonic discharges, and genetic testing confirming SCN4A mutations. Differential diagnoses include myotonia congenita (which exhibits a warm-up phenomenon) and myotonic dystrophy (which includes systemic features such as facial muscle involvement and cataracts). Management typically involves the use of sodium channel blockers such as mexiletine, which is considered first-line therapy for reducing myotonia. Patients are advised to avoid triggers such as cold exposure and strenuous activity. In pregnancy and lactation, mexiletine is usually categorized as having potential risks (typically category C), so a careful risk-benefit assessment is required, and alternative supportive measures may be considered. Option A (Paramyotonia congenita) is correct given the clinical scenario: myotonia that worsens with repetitive exercise, development of transient weakness, and a positive family history. Option B (Myotonic dystrophy) would usually involve multisystem features and a different pattern of muscle involvement, whereas Option C (Myotonia congenita) typically shows improvement (warm-up phenomenon) with repeated contractions. 1. Paramyotonia congenita is characterized by paradoxical myotonia that worsens with repeated activity, unlike the warm-up phenomenon seen in myotonia congenita. 2. Cold exposure is a classic trigger that exacerbates symptoms in this condition. Recent studies focus on the molecular genetics of SCN4A mutations and the pharmacologic management of non-dystrophic myotonias. There is ongoing research into newer sodium channel blockers and genotype\u2013phenotype correlations that may guide personalized therapy in the future.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with Androgen receptor gene defect with findings suggestive of (Kennedy syndrome), asked about what it comes with?",
    "option_a": "DM",
    "option_b": "hepatomegaly",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Kennedy disease, also known as X\u2010linked spinobulbar muscular atrophy, is caused by a mutation (polyglutamine expansion) in the androgen receptor gene. This disease not only causes progressive lower motor neuron degeneration, but also produces endocrine abnormalities due to partial androgen insensitivity. The mutant androgen receptor with an expanded CAG repeat leads to protein misfolding and aggregation in motor neurons, inducing apoptosis and subsequent neurodegeneration. The associated androgen insensitivity contributes to endocrine features such as gynecomastia. This link between the genetic defect and both neuromuscular and endocrine manifestations is well documented in recent molecular studies. Patients typically present in adulthood with progressive bulbar and limb weakness, fasciculations, and muscle cramps. In addition, signs of androgen insensitivity such as gynecomastia and testicular atrophy are frequently observed, helping differentiate Kennedy disease from other motor neuron diseases such as ALS. Diagnosis is confirmed by genetic testing identifying an expanded CAG repeat in the androgen receptor gene. The differential diagnosis includes ALS, which has both upper and lower motor neuron signs but lacks endocrine abnormalities, and other neuromuscular disorders without androgen receptor involvement. There is currently no cure for Kennedy disease; management is primarily supportive, focusing on physical therapy, occupational therapy, and symptomatic relief of neuromuscular symptoms. Endocrine features are managed conservatively. Although the condition mainly affects males, female carriers may have mild symptoms. In the context of pregnancy or lactation (rarely applicable in affected individuals), genetic counseling is important, and any hormonal interventions should be managed with careful risk\u2010benefit assessment. Option A (DM) is incorrect because diabetes mellitus is not a cardinal feature of Kennedy disease. Option B (hepatomegaly) is not associated with this condition. Option C, which corresponds to the presence of gynecomastia (a classic feature due to partial androgen insensitivity), is the correct answer. Option D is not provided. \u2022 Kennedy disease presents with a combination of lower motor neuron signs and endocrine abnormalities (gynecomastia).  \u2022 Genetic testing for CAG repeat expansion is diagnostic.  \u2022 Differentiation from ALS is aided by the presence of endocrine features. Recent research has focused on understanding the molecular basis of protein misfolding in Kennedy disease with hopes to develop targeted therapies. However, current management remains symptomatic, and ongoing trials are investigating agents that reduce protein aggregation and improve neuromuscular function.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of findings suggestive of MMN, dx?",
    "option_a": "MMN",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Multifocal Motor Neuropathy (MMN) is an immune-mediated demyelinating neuropathy that predominantly affects motor nerves, leading to asymmetrical weakness without sensory loss. MMN is thought to be mediated by an autoimmune mechanism, often associated with anti\u2013GM1 IgM antibodies that cause conduction block along motor nerves. This immune attack leads to demyelination and impaired nerve conduction, while sparing sensory fibers. Patients with MMN typically present with slowly progressive, asymmetric weakness, especially in the upper extremities. The absence of sensory deficits and the presence of conduction block on nerve conduction studies help differentiate MMN from disorders such as ALS or typical demyelinating polyneuropathies. The diagnostic workup involves nerve conduction studies to detect multifocal motor conduction blocks without sensory involvement. Differential diagnoses include ALS (which shows both UMN and LMN signs and lacks conduction block) and other demyelinating neuropathies, which often include sensory deficits. The first-line treatment is intravenous immunoglobulin (IVIg), which has been shown to improve strength and function. In refractory cases, immunosuppressive agents such as cyclophosphamide may be considered as second-line therapy. Regarding pregnancy and lactation, IVIg is generally considered safe, but therapy should be individualized after a thorough risk\u2013benefit discussion. Option A (MMN) is correct because the clinical scenario, featuring a motor neuropathy with a conduction block and absence of sensory changes, is typical for MMN. Other options, though not specified, would likely represent conditions with different clinical or electrophysiological features. \u2022 Conduction block on nerve conduction studies is the hallmark of MMN.  \u2022 MMN presents with a purely motor pattern, differentiating it from ALS.  \u2022 Early initiation of IVIg can improve long-term outcomes. Recent clinical guidelines (from the EFNS/PNS and other societies) continue to support IVIg as the cornerstone of MMN therapy. Ongoing studies are investigating additional immunomodulatory therapies to further improve patient outcomes.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "70 years old male patient came with progressive spastic LL weakness progress over time to involve UL, fasciculation present.",
    "option_a": "PLS",
    "option_b": "ALS!!!",
    "option_c": "Hereditary Spastic Paraplegia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized by the concurrent degeneration of upper motor neurons (UMNs) and lower motor neurons (LMNs). This dual involvement is key to its diagnosis. ALS involves multiple pathological mechanisms including glutamate-induced excitotoxicity, oxidative stress, mitochondrial dysfunction, and genetic mutations (e.g., SOD1, C9orf72) leading to neuronal death. The combination of UMN degeneration (resulting in spasticity) and LMN degeneration (resulting in fasciculations and atrophy) underlies the clinical presentation. A 70-year-old male with progressive spastic weakness in the lower limbs that subsequently involves the upper limbs, along with fasciculations, demonstrates the mixed UMN and LMN involvement characteristic of ALS. The presence of fasciculations (a LMN sign) rules out disorders that present solely with UMN signs, such as primary lateral sclerosis (PLS). Diagnosis is primarily clinical, supported by electromyography (EMG) showing widespread denervation and reinnervation. Differential diagnoses include PLS (which features only UMN signs) and hereditary spastic paraplegia (typically presents earlier, with isolated lower limb involvement and without LMN findings such as fasciculations). Management is multidisciplinary and includes disease-modifying therapies such as Riluzole (first-line) and possibly Edaravone as a second agent, which modestly slow disease progression. Supportive care with physical therapy, respiratory support, nutritional management (e.g., gastrostomy for dysphagia), and speech therapy is essential. Although ALS predominantly affects older adults, in the rare cases of young patients or females of childbearing age, the use of medications like Riluzole requires careful evaluation in pregnancy and lactation due to potential teratogenic effects or excretion in breast milk. Option A (PLS) is incorrect because PLS is characterized by only UMN signs without LMN features like fasciculations. Option B (ALS) is correct as the clinical picture of combined UMN and LMN signs fits ALS. Option C (Hereditary Spastic Paraplegia) is unlikely because it generally presents with isolated lower limb spasticity and does not include upper limb involvement or LMN signs such as fasciculations. \u2022 The simultaneous presence of spasticity and fasciculations strongly suggests ALS over PLS.  \u2022 EMG is a critical tool in demonstrating both denervation and reinnervation patterns in ALS.  \u2022 Early multidisciplinary intervention can optimize quality of life in ALS patients. Recent research continues to refine the understanding of ALS pathophysiology, and while agents like Riluzole and Edaravone provide modest benefits, ongoing clinical trials are investigating gene therapies and new neuroprotective agents to change the disease course.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Patient diagnosed with breast cancer underwent chemotherapy and radiation, EMG showed: myokymia came with plexopathy. What is your diagnosis?",
    "option_a": "Radiation induce",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Radiation-induced plexopathy is a recognized complication following radiotherapy, particularly in the treatment of breast cancer. It involves damage to the brachial plexus due to radiation exposure. Radiation can cause progressive fibrosis and direct injury to nerve fibers in the brachial plexus, leading to demyelination and axonal degeneration. This damage may manifest as myokymic discharges on electromyography (EMG), which are rhythmic, spontaneous muscle fiber activities reflecting abnormal nerve excitability. In patients with a history of breast cancer treated with chemotherapy and radiation, the development of plexopathy with accompanying symptoms such as pain, weakness, and paresthesia in the distribution of the affected nerves is characteristic. The presence of myokymia on EMG is particularly suggestive of radiation-induced nerve injury, distinguishing it from neoplastic recurrence, which typically does not produce myokymic discharges. The diagnosis relies on a detailed history of radiation exposure and characteristic EMG findings (myokymia). Differential diagnoses include recurrent neoplastic plexopathy and chemotherapy-induced neuropathy, with imaging studies (e.g., MRI) aiding in differentiation. Metastatic involvement usually presents with more continuous pain and less specific EMG findings. Management is largely supportive, focusing on symptomatic relief through physical therapy, pain management, and sometimes corticosteroids in an attempt to reduce inflammation and fibrosis. There is no definitive disease-modifying treatment. In cases where patients are pregnant or lactating, any subsequent radiation planning must carefully weigh the risks versus benefits; however, once radiation-induced plexopathy has developed, management remains symptomatic and similar regardless of pregnancy status. Option A (Radiation induced) is correct because the patient\u2019s history of radiation therapy combined with the EMG finding of myokymia strongly supports radiation-induced brachial plexopathy. The other options, though not specified, would not encapsulate the characteristic history and electrophysiological findings seen in this scenario. \u2022 Myokymic discharges on EMG are highly indicative of radiation-induced nerve injury.  \u2022 A thorough treatment history is essential in patients presenting with plexopathy following cancer therapy.  \u2022 Distinguishing radiation-induced plexopathy from tumor recurrence is critical for proper management. Advancements in radiation delivery techniques, such as intensity-modulated radiotherapy (IMRT), have decreased the incidence of radiation-induced plexopathy. Ongoing research is exploring anti-fibrotic agents and other interventions to mitigate long-term radiation complications.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with myopathy and malignant hyperthermia, dx?",
    "option_a": "Central core myopathy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Malignant hyperthermia is a life\u2010threatening hypermetabolic state triggered by certain anesthetic agents. Central core myopathy is a congenital myopathy that is notably associated with this condition due to its underlying genetic defect. Central core disease is caused by mutations in the RYR1 gene, which results in abnormal calcium release from the sarcoplasmic reticulum and subsequent muscle fiber dysfunction. This predisposes patients to malignant hyperthermia when exposed to triggering agents like succinylcholine or volatile anesthetics. Clinically, patients may present with muscle weakness and hypotonia. When exposed to triggering anesthetic agents, they can develop a hypermetabolic state characterized by rapid rise in temperature, muscle rigidity, acidosis, and potentially rhabdomyolysis\u2014hallmarks of malignant hyperthermia. Diagnosis involves a detailed clinical and family history, muscle biopsy revealing central cores, and genetic testing for RYR1 mutations. Differential diagnoses include other congenital myopathies such as multi\u2010minicore disease and centronuclear myopathy, which do not carry the same malignant hyperthermia risk. Management is two-fold: for the myopathy, supportive care including physical therapy is recommended; for anesthesia, avoidance of triggering agents is mandatory. In the event of a malignant hyperthermia crisis, prompt treatment with dantrolene is indicated. In pregnancy and lactation, non-triggering anesthetic techniques are crucial, and any medication used should be carefully assessed for fetal or neonatal safety. Option A (Central core myopathy) is correct because its association with RYR1 mutations and a predisposition to malignant hyperthermia is well established. The other options were not provided and would not align with this specific clinical correlation. 1. Always inquire about a history of muscle disorders before administering anesthesia. 2. Dantrolene is the treatment of choice in a malignant hyperthermia crisis. Recent guidelines emphasize preoperative screening for RYR1 mutations in patients with congenital myopathies and advocate for the use of non-triggering anesthetic regimens in at-risk populations.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with inner arm and forearm tingling sensation, thenar muscles weakness, pain when raising arm, where is the localization? \u0645\u0643\u0631\u0631",
    "option_a": "C8-T1",
    "option_b": "C7, C8",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Accurate nerve root localization requires knowledge of dermatomal and myotomal distributions. Specific patterns of sensory changes and motor deficits help narrow down the level of lesion in cervical radiculopathies. Compression or irritation of the lower cervical nerve roots\u2014specifically C8 and T1\u2014can disrupt nerve conduction. This results in sensory disturbances along the inner (medial) arm and forearm, as well as motor deficits in muscles innervated by fibers from these roots. A patient presenting with tingling on the inner aspect of the arm and forearm, combined with thenar muscle weakness (affected by median nerve fibers arising predominantly from C8\u2013T1), is indicative of a lesion affecting these specific nerve roots. The pain on raising the arm may also reflect dynamic nerve tension or compression. Evaluation should include a detailed neurological examination, electromyography (EMG), nerve conduction studies (NCS), and imaging\u2014particularly MRI of the cervical spine\u2014to assess for possible disc herniation or foraminal narrowing. Differential diagnoses include brachial plexitis and entrapment neuropathies, which can be differentiated through their distinct clinical and electrophysiological findings. First-line management usually involves conservative treatment with physical therapy and non-steroidal anti-inflammatory drugs (NSAIDs). Epidural steroid injections may be considered for persistent symptoms. In refractory cases, surgical intervention might be required. For pregnant and lactating patients, physical therapy is preferred, and NSAIDs are used with caution\u2014particularly in the third trimester\u2014to avoid adverse effects on the fetus or infant. Option A (C8\u2013T1) is correct because the inner arm and forearm sensory disturbances along with thenar weakness most accurately reflect lower brachial plexus involvement. Option B (C7, C8) would more typically produce deficits involving additional muscle groups (like the triceps) and different sensory distributions. 1. A thorough understanding of dermatomal maps is critical in localizing cervical radiculopathies. 2. Involvement of C8\u2013T1 typically presents with both sensory and motor deficits in the hand, particularly affecting median nerve-innervated muscles. Contemporary studies support the integration of clinical examination with advanced imaging and electrodiagnostic testing to improve the diagnostic accuracy of cervical radiculopathies, guiding both conservative and surgical treatment strategies.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with findings suggestive of hmsn1, has pmp22 duplication, biopsy finding?",
    "option_a": "Onion bulb",
    "option_b": "Sausage like demyelination",
    "option_c": "Axonal injury",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary motor and sensory neuropathy type 1 (HMSN 1), also known as Charcot-Marie-Tooth disease type 1, is typically a demyelinating neuropathy associated with PMP22 gene duplication. Duplication of the PMP22 gene results in abnormal myelin production. Repeated cycles of demyelination and remyelination ensue, leading to the formation of onion bulb structures\u2014concentric layers of Schwann cell processes\u2014on nerve biopsy. Patients often present with a slowly progressive course of distal muscle weakness, atrophy, and sensory deficits. Foot deformities such as pes cavus are common, correlating with the chronic demyelinating process seen in nerve conduction studies and biopsy. Diagnosis is confirmed through a combination of clinical examination, nerve conduction studies (which show slowed conduction velocities), genetic testing for PMP22 duplication, and nerve biopsy demonstrating onion bulb formations. Differential diagnoses include inflammatory demyelinating polyneuropathies like chronic inflammatory demyelinating polyneuropathy (CIDP), which typically show sausage-like demyelination. Management is supportive, focusing on physical therapy, orthotic devices, and sometimes surgical correction of foot deformities. There is no curative treatment for CMT. In pregnancy and lactation, management remains conservative with an emphasis on physical support and genetic counseling, while avoiding teratogenic medications. Option A (Onion bulb) is correct because it is the hallmark histopathological finding in demyelinating neuropathies like CMT1. Option B (Sausage-like demyelination) is more typical of inflammatory disorders such as CIDP, and Option C (Axonal injury) is characteristic of CMT type 2. 1. CMT1A, the most common form of CMT, is strongly associated with PMP22 duplication. 2. Onion bulb formations on nerve biopsy are pathognomonic for repeated cycles of demyelination and remyelination. Recent advances emphasize early genetic screening and precise electrophysiological evaluation to differentiate CMT subtypes. Emerging research is exploring potential molecular therapies targeting PMP22 expression.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a young patient with congenital MG (has a history suggestive of slow channel type) rx?",
    "option_a": "Pyridostigmine",
    "option_b": "3,4 DAP",
    "option_c": "fluoxetine",
    "option_d": "quinidine",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders characterized by impaired neuromuscular transmission. The slow channel type specifically involves prolonged opening of the acetylcholine receptor channels. In slow channel CMS, mutations cause the acetylcholine receptor to remain open longer than normal. This results in excessive influx of calcium into the postsynaptic muscle membrane, leading to endplate myopathy and muscle weakness. Unlike autoimmune myasthenia gravis, this condition is genetic and does not respond to cholinesterase inhibitors. Patients, often young, present with fatigable weakness. Unlike typical myasthenia gravis, congenital forms like slow channel syndrome manifest early in life and are not mediated by antibodies. The prolonged channel opening leads to muscle weakness and potential degeneration of the neuromuscular junction. Diagnosis is based on clinical history, electrophysiological testing (repetitive nerve stimulation), and genetic studies confirming the mutation responsible for the slow channel phenotype. It is important to differentiate CMS from autoimmune myasthenia gravis, where antibody tests (against acetylcholine receptors) would be positive. The mainstay of treatment for slow channel CMS is the use of open-channel blockers. Quinidine is traditionally used to reduce prolonged acetylcholine receptor activation. Alternatives such as fluoxetine have also been employed. In pregnancy and lactation, the use of quinidine requires careful risk-benefit analysis given its potential effects on the fetus and nursing infant, with a multidisciplinary approach recommended. Option D (quinidine) is the correct treatment as it serves as an open channel blocker to mitigate the prolonged receptor activation seen in slow channel CMS. Option A (pyridostigmine) is contraindicated because it can exacerbate symptoms. Option B (3,4 DAP) is not indicated in this setting, and while Option C (fluoxetine) has been used, quinidine remains the classical choice. 1. Cholinesterase inhibitors are often contraindicated in slow channel congenital myasthenic syndrome. 2. Open channel blockers such as quinidine are the mainstay of therapy in this condition. Recent studies continue to support the use of quinidine in managing slow channel CMS, although newer agents like fluoxetine are being considered for their potentially improved safety profiles, especially in patients where teratogenic risk must be minimized.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with Vit B12 deficiency (hints: involving vibration and proprioception) however vit b12 levels is upper normal level, what to order?",
    "option_a": "Homocysteine ( if their methylmalonic it will be the answer )",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "In cases of suspected vitamin B12 deficiency, particularly in patients exhibiting neurological signs such as impaired vibration and proprioception (subacute combined degeneration), a normal upper\u2010range B12 level may be misleading. Functional B12 deficiency can be detected by assessing metabolic markers that build up when B12 is insufficient. Vitamin B12 is a cofactor for the conversion of methylmalonyl-CoA to succinyl-CoA and for the remethylation of homocysteine to methionine. In deficiency states, methylmalonic acid (MMA) accumulates (a more specific marker) along with homocysteine. Although homocysteine can be elevated in both folate and B12 deficiencies, elevated MMA is more specific to B12 deficiency and reflects disturbed myelin synthesis contributing to neurological symptoms. Patients with functional vitamin B12 deficiency may present with dorsal column dysfunction (loss of vibration and proprioception), and sometimes a mild or borderline serum B12 level. This apparent discrepancy necessitates additional metabolic testing to confirm deficiency. Common differentials include folate deficiency, peripheral neuropathies (e.g., diabetic neuropathy), and other causes of posterior column dysfunction. When clinical suspicion remains high despite normal serum B12, metabolic assays such as serum methylmalonic acid and homocysteine levels are used. MMA is preferred due to its higher specificity for B12 deficiency. Once confirmed by elevated methylmalonic acid, treatment with vitamin B12 injections (typically intramuscular cyanocobalamin or hydroxocobalamin) is initiated. In pregnancy and lactation, parenteral B12 is recommended as it is safe and effective. Monitoring of neurological recovery and periodic reassessment of B12 and metabolite levels is advised in all patients. Option A suggested measuring homocysteine, which is indeed elevated in B12 deficiency but is less specific because it may also be raised in folate deficiency. Option B (though not fully described) is inferred to indicate ordering the methylmalonic acid level, making it the best choice. Options C and D are either absent or irrelevant here. 1. Normal serum B12 levels can mask a functional deficiency; always consider metabolic markers in the appropriate clinical context. 2. Elevated methylmalonic acid is a highly specific indicator of vitamin B12 deficiency. 3. Neurological manifestations can precede hematologic abnormalities in B12 deficiency. Recent guidelines and research emphasize the role of methylmalonic acid measurement in cases of suspected B12 deficiency with normal serum levels. This approach has been validated by studies showing improved diagnostic accuracy, ensuring that patients receive timely treatment.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case scenario of a patient with findings suggestive of Myotonic dystrophy, asked about the gene?\nCataract is the first sign",
    "option_a": "CTG (CTG REPEAT)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonic dystrophy is a multisystem disorder that primarily affects skeletal muscles, but also has involvement of the eye (early cataracts), heart, endocrine organs, and brain. The condition is genetically mediated by a trinucleotide repeat expansion. Myotonic dystrophy type 1 is caused by an unstable CTG trinucleotide repeat expansion in the Dystrophia Myotonica Protein Kinase (DMPK) gene. This mutation leads to toxic RNA accumulation which interferes with the normal splicing of several other genes, thereby producing the multisystem clinical picture. Patients often present with myotonia, muscle weakness, early cataracts (which may be the first sign), and various systemic manifestations such as cardiac conduction defects and endocrine disturbances. The genetic defect underlies all these diverse manifestations. The differential diagnosis includes other muscular dystrophies and myotonic disorders. Definitive diagnosis is achieved by genetic testing demonstrating the CTG repeat expansion in the DMPK gene. Electromyography (EMG) can support the clinical suspicion by showing myotonic discharges. There is no cure; management is symptomatic and multidisciplinary. Regular cardiac evaluations, physical therapy, and surveillance for endocrine and ocular complications are recommended. In pregnancy, prenatal genetic counseling is essential due to the risk of anticipation and congenital myotonic dystrophy. Option A correctly identifies the gene abnormality as a CTG trinucleotide repeat expansion, which is the hallmark of myotonic dystrophy type 1. Other options (B, C, D) are either not provided or do not represent the underlying genetic defect in DM1. 1. Early-onset cataracts in a patient with myotonia should raise suspicion for myotonic dystrophy. 2. The genetic defect shows anticipation, meaning that symptoms can become more severe in successive generations. 3. Multisystem assessment is crucial for managing these patients. Recent studies continue to focus on the RNA toxicity mechanism as a potential target for therapeutic intervention. Updated guidelines emphasize early genetic counseling and a multidisciplinary approach to manage the varied systemic manifestations.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Case of SMA, asked which of the following is a supportive finding",
    "option_a": "Neurogenic finding on EMG",
    "option_b": "Abnormal respiratory function test",
    "option_c": "Cardiomyopathy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder characterized by degeneration of anterior horn cells. One of the supportive diagnostic findings is the presence of neurogenic changes on electromyography (EMG). SMA is most commonly due to mutations in the Survival Motor Neuron 1 (SMN1) gene. The resultant deficiency in the SMN protein leads to motor neuron degeneration, muscle atrophy, and subsequently, the classic neurogenic abnormalities detectable on EMG. Clinically, SMA presents with progressive, symmetric muscle weakness, often with fasciculations. Electrophysiologic studies typically show signs of denervation such as fibrillations and reduced recruitment of motor units, supporting the diagnosis. Differential diagnoses include congenital myopathies, muscular dystrophies, and peripheral neuropathies. The EMG helps differentiate SMA (a neurogenic process) from myopathic conditions. Definitive diagnosis is confirmed by genetic testing for SMN1 deletion. Recent management includes disease-modifying therapies such as nusinersen, onasemnogene abeparvovec, and risdiplam, which aim to increase SMN protein levels. Supportive care including respiratory support, physiotherapy, and nutritional management is essential. In pregnancy and lactation, treatment options need careful consideration; genetic counseling and careful risk\u2013benefit analysis of medications are recommended. Option A, indicating neurogenic findings on EMG, is a supportive finding in SMA. Option B (abnormal respiratory function tests) may be seen as a complication rather than a diagnostic support. Option C (cardiomyopathy) is not typically associated with SMA. 1. Neurogenic changes on EMG are a cornerstone supportive finding in SMA. 2. Genetic testing for SMN1 deletion remains the gold standard for diagnosis. 3. Early intervention can improve outcomes, particularly with new disease\u2010modifying therapies. Recent clinical trials have demonstrated the benefits of early treatment with SMN-enhancing therapies. Guidelines now advocate for early genetic screening and multidisciplinary management to optimize patient outcomes.",
    "exam_year": "2021",
    "exam_type": "Part I"
  },
  {
    "question": "Most sensitive test for notes the is Gravis",
    "option_a": "Small fiber EMG",
    "option_b": "Anti-Cholinesterase antibody",
    "option_c": "Anti-MuSK",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia Gravis (MG) is an autoimmune disorder affecting the neuromuscular junction, characterized by fluctuating muscle weakness. Diagnostic confirmation often involves electrophysiological testing, and the single-fiber electromyography (SFEMG) is recognized as the most sensitive test for detecting neuromuscular transmission abnormalities. In MG, autoantibodies are directed against postsynaptic components of the neuromuscular junction (most commonly acetylcholine receptors), impairing neuromuscular transmission. SFEMG is able to detect increased 'jitter' and intermittent blocking which reflect these transmission defects. Clinically, MG patients often present with fatigable muscle weakness, frequently affecting ocular muscles (ptosis, diplopia) initially. The SFEMG, by recording the variability in neuromuscular transmission, correlates well with the clinical fluctuations seen in these patients. Differential diagnoses include Lambert\u2013Eaton syndrome, congenital myasthenic syndromes, and other disorders causing fluctuating weakness. Other tests include repetitive nerve stimulation and antibody assays (anti-AChR and anti-MuSK). However, SFEMG remains the most sensitive tool, especially in borderline cases. Management involves acetylcholinesterase inhibitors (e.g., pyridostigmine) as first-line therapy, followed by immunosuppressive agents (such as corticosteroids, azathioprine, or mycophenolate mofetil) for more severe cases. Thymectomy is considered in certain patients. In pregnant and lactating women, pyridostigmine is generally safe; however, immunosuppressive strategies require careful monitoring due to potential teratogenic effects. Option A is described as 'Small fiber EMG'. Although the standard term is 'Single fiber EMG', it is clearly intended to represent the test with the highest sensitivity for MG. Option B (Anti-Cholinesterase antibody) is not a standard diagnostic marker, and Option C (Anti-MuSK) is relevant only in a subset of MG patients. Thus, Option A is the most sensitive test when correctly interpreted as single fiber EMG. 1. Single fiber EMG is the most sensitive electrophysiological test for diagnosing MG, detecting subtle transmission defects. 2. The presence of fluctuating muscle weakness and ocular symptoms is highly suggestive of MG. 3. Negative antibody tests do not rule out MG; electrophysiological testing becomes especially important in such cases. Recent research reinforces the role of SFEMG in the early and accurate diagnosis of MG. Updated guidelines also support its use in seronegative cases, and emerging therapies are aimed at targeted immunomodulation based on antibody profiles.",
    "exam_year": "2021",
    "exam_type": "Part I"
  }
]